IRIS
MERLINI, GIAMPAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.154
AS - Asia 13.920
EU - Europa 10.443
SA - Sud America 1.790
Continente sconosciuto - Info sul continente non disponibili 807
AF - Africa 502
OC - Oceania 32
AN - Antartide 1
Totale 49.649
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.303
CN - Cina 6.349
SG - Singapore 3.269
IE - Irlanda 2.557
HK - Hong Kong 1.506
BR - Brasile 1.301
VN - Vietnam 1.253
RU - Federazione Russa 1.206
FI - Finlandia 1.106
IT - Italia 1.092
UA - Ucraina 1.086
DE - Germania 1.061
FR - Francia 681
GB - Regno Unito 536
SE - Svezia 490
CA - Canada 353
IN - India 335
ZA - Sudafrica 282
BD - Bangladesh 222
AR - Argentina 158
MX - Messico 133
JP - Giappone 132
IQ - Iraq 112
TR - Turchia 95
PL - Polonia 88
CO - Colombia 85
ES - Italia 85
NL - Olanda 83
PK - Pakistan 79
BE - Belgio 72
ID - Indonesia 67
VE - Venezuela 65
EC - Ecuador 62
CR - Costa Rica 55
AT - Austria 53
IL - Israele 52
PH - Filippine 52
SA - Arabia Saudita 49
JM - Giamaica 46
MA - Marocco 44
UZ - Uzbekistan 44
HN - Honduras 41
NI - Nicaragua 39
SV - El Salvador 37
CL - Cile 36
TT - Trinidad e Tobago 33
CZ - Repubblica Ceca 32
KE - Kenya 32
LT - Lituania 31
GT - Guatemala 30
PY - Paraguay 30
IR - Iran 29
AE - Emirati Arabi Uniti 28
JO - Giordania 27
MY - Malesia 26
PR - Porto Rico 25
AU - Australia 24
GR - Grecia 23
TN - Tunisia 22
CW - ???statistics.table.value.countryCode.CW??? 21
KZ - Kazakistan 21
AL - Albania 20
NP - Nepal 19
DK - Danimarca 18
EG - Egitto 18
ET - Etiopia 17
GP - Guadalupe 17
MU - Mauritius 17
PE - Perù 17
UY - Uruguay 17
BO - Bolivia 16
DZ - Algeria 16
PT - Portogallo 16
AZ - Azerbaigian 14
KG - Kirghizistan 14
KR - Corea 14
LB - Libano 13
TH - Thailandia 13
EE - Estonia 12
LV - Lettonia 12
RO - Romania 12
SC - Seychelles 11
BG - Bulgaria 10
CH - Svizzera 10
EU - Europa 10
HU - Ungheria 10
PA - Panama 10
AM - Armenia 9
PS - Palestinian Territory 9
BB - Barbados 8
HR - Croazia 8
OM - Oman 8
SY - Repubblica araba siriana 8
NZ - Nuova Zelanda 7
CY - Cipro 6
DO - Repubblica Dominicana 6
LK - Sri Lanka 6
NG - Nigeria 6
SN - Senegal 6
BH - Bahrain 5
Totale 48.751
Salva come PNG Salva come JPEG
Città #
Dublin 2.550
Chandler 2.426
San Jose 2.297
Ashburn 1.814
Singapore 1.615
Jacksonville 1.529
Hong Kong 1.469
Nanjing 1.319
Dallas 1.261
Council Bluffs 1.177
Beijing 1.032
Boardman 812
Nanchang 564
Princeton 530
Lawrence 489
Wilmington 476
Lauterbourg 471
Los Angeles 456
Ho Chi Minh City 429
Shenyang 403
Medford 397
Hebei 380
Helsinki 349
Changsha 343
Hanoi 313
Jiaxing 304
Ann Arbor 276
New York 269
Tianjin 248
Johannesburg 235
Hangzhou 223
Buffalo 222
Santa Clara 216
Redondo Beach 192
Moscow 191
Munich 180
Milan 167
Shanghai 163
São Paulo 129
Pavia 128
Woodbridge 112
Tokyo 109
Orem 104
Norwalk 101
Chicago 99
Atlanta 89
Frankfurt am Main 83
Toronto 82
Da Nang 79
Montreal 79
Brooklyn 76
Rome 75
Turku 74
Piscataway 69
Warsaw 69
Brussels 68
Chennai 65
North Bergen 65
Seattle 65
London 64
Fairfield 63
Verona 63
Denver 58
San Francisco 58
Phoenix 57
Guangzhou 53
Washington 53
Des Moines 50
Houston 50
Stockholm 49
The Dalles 48
Zhengzhou 48
Baghdad 47
Nuremberg 46
Ningbo 44
Rio de Janeiro 44
Haiphong 42
Mexico City 42
Columbus 41
Falkenstein 41
Amsterdam 39
Bologna 38
Boston 38
Tashkent 37
Managua 36
Manchester 36
Naples 36
Pune 36
San José 36
Charlotte 32
Hải Dương 30
Jinan 30
Brasília 29
Ankara 28
Dhaka 28
San Salvador 28
Belo Horizonte 27
Biên Hòa 27
Curitiba 27
Kunming 27
Totale 31.313
Salva come PNG Salva come JPEG
Nome #
Susceptibility to AA amyloidosis in rheumatic diseases: A critical overview. 242
Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: Results from a large cohort of patients 229
Pharmacokinetic behavior of Rituximab: a study of different schedules of administration for heterogeneous clinical settings. 177
A novel method for proteomic analysis of immunoglobulin light chains and attribution to a germline gene-based family 173
A modified high-dose dexamethasone regimen for primary systemic amyloidosis 169
Fibrillazione atriale e amiloidosi cardiaca AL: un connubio intrigante 167
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis 166
Liver biopsy discloses a new apolipoprotein AI hereditary amyloidosis in several unrelated Italian families 162
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study 159
Valore prognostico della presenza di bassi voltaggi elettrocardiografici nei pazienti affetti da amiloidosi AL 158
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 149
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 149
Amyloid fibrils derived from the apolipoprotein A1 Leu174Ser variant contain elements of ordered helical structure. 148
A Strategy for Synthesis of Pathogenic Human Immunoglobulin Free Light Chains in E-coli 147
A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. 146
A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. 146
Amyloid typing: immunoelectron microscopy 146
Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis 145
Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis 144
Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. 143
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils:inhibition of amyloidogenesis. 143
AMICA: an electronic patient record specifically designed for an amyloidosis network 143
Advantages of the lognormal approach to determining reference change values for N-terminal propeptide B-type natriuretic peptide 143
Characterization of the two unique human anti-flavin monoclonal immunoglobulins. 141
Abnormalities in thrombin-antithrombin pathway in primary systemic amyloidosis. 141
A partially structured species of beta 2-microglobulin is significantly populated under physiological conditions and involved in fibrillogenesis 140
Beta2-microglobulin isoforms display an heterogeneous affinity for type I collagen. 139
Amino acid sequence of k Sci, the Bence Jones protein isolated from a patient with light chain deposition disease. 138
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis 138
“Separation and quantification of two beta2-microglobulin isoforms”. 137
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. 137
A novel approach for the purification and proteomic analysis of pathogenic immunglobulin free light chains from serum 136
Heavy chain disease can be detected by capillary zone electrophoresis. 136
A patient with AL amyloidosis with negative free light chain results 136
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis 136
Amyloidogenic light chains induce human cardiac fibroblast toxicity through alteration of mitochondrial functionality 136
Obstructive intramural coronary amyloidosis: a distinct phenotype of cardiac amyloidosis that can cause acute heart failure. 135
AMYLOIDOSIS AL 135
Characterization of immunoglobulin variable regions of two human pathogenic monoclonal cryocrystalglobulins 135
Analysis of Vlambda-Jlambda expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambda III) as a new amyloid-associated germline gene segment 135
The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity 135
Acute phase proteins and prognosis in multiple myeloma. 135
Structural characterization of kappa II Inc, a new amyloid immunoglobulin 134
AL amyloidosis. Characterization of amyloidogenic cells by anti-idiotypic monoclonal antibodies 134
A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis 134
Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy 134
Reasoning with Effects of Clinical Guideline Actions Using OWL: AL Amyloidosis as a Case StudyKnowledge Representation for Health-Care 134
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 133
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis 133
Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis 132
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 132
Bevacizumab treatment followed by maintenance in life-threatening POEMS syndrome. 131
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients 131
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. 131
4'-iodo-4'-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. 130
Autologous stem cell transplantation following heart transplantation for AL amyloidosis 130
Waldenstrom macroglobulinemia 130
Metodo per la separazione e la quantificazione di due conformazioni di beta-2-microglobulina in equilibrio dinamico 130
Cardiac light chain amyloidosis: The role of metal ions in oxidative stress and mitochondrial damage 130
Nutritional status evaluation of patients affected by al amyloidosis: a pilot study 129
Utility of biochemicalmarkers in the follow-up of heart transplant recipients 129
Clotting alterations in primary systemic amyloidosis. 129
Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis 129
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 129
ATR-FTIR spectroscopy supported by multivariate analysis for the characterization of adipose tissue aspirates from patients affected by systemic amyloidosis 129
Bone marrow amyloidosis. 128
Hereditary amyloidosis 128
Cardiac immunocyte-derived (AL) amyloidosis: an endomyocardial biopsy study in 11 patients 128
Effects of the Known Pathogenic Mutations on the Aggregation Pathway of the Amyloidogenic Peptide of Apolipoprotein A-I. 128
Abnormalities in thrombin-antithrombin pathway in AL amyloidosis. 128
International prognostic scoring system for Waldenstrom macroglobulinemia 127
Use of anti-(beta2 microglobulin) mAb to study formation of amyloid fibrils 126
A practical approach to the diagnosis of systemic amyloidoses 125
Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine 124
Characterization of the new serum protein reference material ERM-DA470k/IFCC: value assignment by immunoassay. 124
In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study 124
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide 123
Clinical, radiological, and biochemical features of a bilateral buttock amyloidoma emerging after 27 years of hemodialysis. 123
A plea to overcome th concept of "staging" and related inadequacy in multiple myeloma. 122
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib and thalidomide 122
A prospective, controlled, nonrandomized study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple-myeloma. 122
4'-Iodo-4'-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid 122
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 121
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies 121
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 120
Investigating heart-specific toxicity of amyloidogenic immunoglobulin light chains: A lesson from C. elegans 120
Repurposing diflunisal for familial amyloid polyneuropathy: A randomized clinical trial 120
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 120
Comparison of three strategies for myocardial protection during coronary artery bypass graft surgery based on markers of cardiac damage. 119
Biological variation of N-terminal pro-brain natriuretic peptide in healthy individuals. 119
A prospective, controlled, non-randomized study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple myeloma. 119
Biochemical markers in early diagnosis and management of systemic amyloidoses 119
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis 119
Prognostication of survival and progression to dialysis in AA amyloidosis 119
Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis 118
Holter monitoring in AL amyloidosis: prognostic implications. 118
AMICA: an electronic patient record specifically designed for an amyloidosis network. 118
AL Amyloidosis Associated with IgM Monoclonal Protein: A Distinct Clinical Entity 118
Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: Avoiding misdiagnosis of a treatable hereditary neuropathy 118
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis 117
Totale 13.579
Salva come PNG Salva come JPEG
Categoria #
all - tutte 228.775
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 228.775
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.951 0 0 0 0 42 59 34 143 128 72 317 1.156
2022/20236.981 815 460 81 552 667 735 22 375 2.973 38 156 107
2023/20242.324 289 458 101 200 259 538 41 145 21 63 121 88
2024/20256.414 135 574 179 216 112 323 231 398 1.636 231 757 1.622
2025/202616.459 1.203 1.186 1.714 1.880 2.070 727 3.162 684 1.478 1.173 588 594
2026/20274.990 513 892 1.211 2.090 284 0 0 0 0 0 0 0
Totale 49.649